Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | CTSG | P08311 | 1/20 | 0.59 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.59 |
| ▸ | CMA1 | P23946 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8028984 | 0.94 | HDAC6 (0.68) | NAAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8019515 | 0.94 | HDAC6 (0.68) | NAAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3679714 | 0.94 | PRSS1 (0.63) | NAAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8029208 | 0.93 | HDAC1 (0.66) | NAAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8032587 | 0.90 | HDAC1 (0.58) | NAAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8019496 | 0.90 | HDAC6 (0.66) | NAAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10865405 | 0.89 | PRSS1 (0.76) | NAAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4932187 | 0.88 | POLB (0.70) | NAAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4931676 | 0.88 | POLB (0.70) | NAAAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4930836 | 0.88 | POLB (0.70) | NAAAHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018132905-A1 | COMPOUNDS FOR TREATMENT OF GLIOBLASTOMA | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2018-07-26 | — | — | WO | disclosed |
| CN-105873588-A | Compounds for the treatment of cancer and uses thereof | 戈里奥诺瓦公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160214958-A1 | COMPOUNDS AND USE FOR TREATING CANCER | GLIONOVA AB (SE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214958-A1 | COMPOUNDS AND USE FOR TREATING CANCER | GLIONOVA AB (SE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214958-A1 | COMPOUNDS AND USE FOR TREATING CANCER | GLIONOVA AB (SE) | 2016-07-28 | — | — | US | disclosed |
| EP-3043801-A2 | COMPOUNDS AND USE FOR TREATING CANCER | Glionova AB (SE) | 2016-07-20 | — | — | EP | disclosed |
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-7880020-B2 | e.g trichlorostatin A; antiproliferative agent; for treating cancer and psoriasis | TOPOTARGET UK LIMITED (GB) | 2011-02-01 | — | — | US | disclosed |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-7569724-B2 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | NAAA 652/4885HDAC3 6/4885HDAC4 9/4885 |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC3 | NAAA 420/4885HDAC3 3/4885HDAC4 7/4885 |
| US-20160214958-A1 | COMPOUNDS AND USE FOR TREATING CANCER | KRAS, NRAS, HRAS | NAAA 3091/4885HDAC3 818/4885HDAC4 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.